Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer.

Han, Ernest S; Wen, Wei; Dellinger, Thanh H; Wu, Jun; Lu, Selena A; Jove, Richard; Yim, John H

Han, Ernest S; Wen, Wei; Dellinger, Thanh H; Wu, Jun; Lu, Selena A; Jove, Richard; Yim, John H.

Afiliação

Han ES; Department of Surgery, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Wen W; Department of Surgery, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Dellinger TH; Department of Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Wu J; Department of Surgery, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Lu SA; Department of Comparative Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Jove R; Department of Surgery, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Yim JH; Department of Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Oncotarget ; 9(36): 24304-24319, 2018 May 11.

Article em En | MEDLINE | ID: mdl-29849942

Palavras-chave

combination; ovarian; paclitaxel; ruxolitinib; synergy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google